| Perifosine May Offer New Mesothelioma Treatment |
The makers of the anti-cancer drug perifosine say new research suggests the drug may offer a new way to fight malignant mesothelioma.
The research article entitled "Perifosine as a Potential Novel Anti-Cancer Agent Inhibits EGFR/MET-AKT Axis in Malignant Pleural Mesothelioma" was recently published in the peer-reviewed online medical journal Plos One. The announcement has been picked up by other news outlets because of the rarity of new treatments for mesothelioma, the asbestos-linked cancer that is diagnosed in about 2,500 Americans every year.
In the new study, perifosine was tested on human mesothelial cells and a variety of mesothelioma cell lines to demonstrate its effectiveness alone or in combination with other mesothelioma treatments. When given at a high enough dose, perifosine interfered with the membranes of mesothelioma cells and halted their growth. The effect was even more pronounced when mesothelioma cells were treated with a combination of perifosine and the chemotherapy drug cisplatin.
Perifosine is an oral anti-cancer drug that inhibits the cell's ability to utilize Akt, a protein kinase that plays a key role in multiple cellular processes including glucose metabolism, apoptosis (cell death) and cell proliferation. Perifosine is currently in a Phase 3 clinical trial for the blood cancer multiple myeloma and has been given Orphan Drug and Fast Track status for this indication.
In a summary of their findings, the Italian-based research team concluded, "This study provides a novel mechanism of action of perifosine, directly inhibit EGFR/MET-AKT1/3 axis, providing a rationale for a novel translational approach to the treatment of Malignant Mesothelioma."
Sources:
Pinton, G et al, "Perifosine as a Potential Novel Anti-Cancer Agent Inhibits EGFR/MET-AKT Axis in Malignant Pleural Mesothelioma" PLoS ONE, May 2012.
"Aeterna Zentaris: Article on Perifosine as Potential Novel Approach to Treatment of Mesothelioma Published in Plos One", May 31, 2012, PR Newswire, Marketwatch.com.
© Surviving Mesothelioma and Cancer Monthly. All rights reserved.
DISCLAIMER: : Surviving Mesothelioma® is registered with the United States Patent and Trademark Office by Cancer Monthly, Inc. and the website is owned and managed by Cancer Monthly Inc. All of the information provided on this website or by any employee or contractor of Cancer Monthly is for informational purposes only. This website is not a substitute for professional medical advice, examination, diagnosis or treatment. This website should not be used for diagnosing or treating a health problem or disease and it is not a substitute for professional care. You should always seek the advice of your physician or other qualified health professional before starting any new treatment or making any changes to an existing treatment. You should not delay in seeking or disregard medical advice based on information on this website or by any employee or contractor of Cancer Monthly.
